BioPharma Dive July 16, 2024
Orum, whose technology is similar to antibody-drug conjugates, will receive $15 million upfront from Vertex under the research collaboration.
Vertex Pharmaceuticals is exploring new ways to prepare patients for intensive therapies like its sickle cell treatment Casgevy, announcing Tuesday a deal with Orum Therapeutics to develop a different kind of conditioning regimen than the chemotherapies that are currently used.
Under the terms of the partnership, Vertex will pay Orum $15 million for rights to study the biotechnology company’s so-called degrader-antibody conjugates, or DACs, as a preconditioning agent for gene editing medicines. After a set period of research, Vertex will have an option to license a DAC for each target covered by the collaboration. Orum can receive as much as $310...
Today's Sponsors
Today's Sponsor